Meanwhile, in SAT, we reported nonsignificant differences (Figure 5A), but in VAT, we reported lower OLFM2 mRNA expression in NASH patients than in non-NASH patients (Figure 5B). The gene discussed is OLFM2; the disease is metabolic dysfunction-associated steatohepatitis.